GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Accustem Sciences Inc (OTCPK:ACUT) » Definitions » EBITDA Margin %

Accustem Sciences (Accustem Sciences) EBITDA Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Accustem Sciences EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Accustem Sciences's EBITDA for the three months ended in Mar. 2024 was $-0.53 Mil. Accustem Sciences's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Accustem Sciences's EBITDA margin for the quarter that ended in Mar. 2024 was 0.00%.


Accustem Sciences EBITDA Margin % Historical Data

The historical data trend for Accustem Sciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accustem Sciences EBITDA Margin % Chart

Accustem Sciences Annual Data
Trend Dec22 Dec23
EBITDA Margin %
- -

Accustem Sciences Quarterly Data
Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Accustem Sciences's EBITDA Margin %

For the Biotechnology subindustry, Accustem Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Accustem Sciences's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Accustem Sciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Accustem Sciences's EBITDA Margin % falls into.



Accustem Sciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Accustem Sciences's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-2.047/0
= %

Accustem Sciences's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-0.526/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Accustem Sciences  (OTCPK:ACUT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Accustem Sciences EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Accustem Sciences's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Accustem Sciences (Accustem Sciences) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
5 Penn Plaza, Suite 1954, Floor 19, New York, NY, USA, 10001
Accustem Sciences Inc is a life sciences company dedicated to optimizing outcomes for all patients with cancer across the globe. The company takes a holistic view of its role in oncology to empower patients and care team with critical answers and tools and drive innovation in healthcare.